Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Presti

Showing results (91-100 of 99) with videos related to

Pageof 10
Sort By:
You have reached the last page of results.This site can display upto 99 results.
Medrxiv : the Preprint Server for Health Sciences|April 14, 2021
Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2Parakkal Deepak, Wooseob Kim, Michael A Paley, et al.
JCI Insight|February 24, 2025
Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infectionMyra Happe, Rebecca M Lynch, Carl J Fichtenbaum, et al.
The Journal of Infectious Diseases|August 10, 2023
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2003
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer GroupF H van Wijk, M S Aapro, G Bolis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL TrialYouyi Fong, Lauren Dang, Bo Zhang, et al.
Vaccine|February 16, 2026
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distancesFei Heng, Craig A Magaret, Nadine G Rouphael, et al.
Nature Communications|January 17, 2025
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boostBo Zhang, Youyi Fong, Lauren Dang, et al.
Nature Medicine|August 28, 2023
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trialAngela R Branche, Nadine G Rouphael, David J Diemert, et al.
Medrxiv : the Preprint Server for Health Sciences|July 28, 2022
SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary AnalysesAngela R Branche, Nadine G Rouphael, David J Diemert, et al.
Pageof 10

Showing results (91-100 of 99) with videos related to

Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 99 results.
Medrxiv : the Preprint Server for Health Sciences|April 14, 2021
Glucocorticoids and B Cell Depleting Agents Substantially Impair Immunogenicity of mRNA Vaccines to SARS-CoV-2Parakkal Deepak, Wooseob Kim, Michael A Paley, et al.
JCI Insight|February 24, 2025
Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infectionMyra Happe, Rebecca M Lynch, Carl J Fichtenbaum, et al.
The Journal of Infectious Diseases|August 10, 2023
Immunogenicity of a 2-Dose Regimen of Moderna mRNA Beta/Omicron BA.1 Bivalent Variant Vaccine Boost in a Randomized Clinical TrialNadine G Rouphael, Angela R Branche, David J Diemert, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 25, 2003
Doxorubicin versus doxorubicin and cisplatin in endometrial carcinoma: definitive results of a randomised study (55872) by the EORTC Gynaecological Cancer GroupF H van Wijk, M S Aapro, G Bolis, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|September 26, 2024
Neutralizing Antibody Immune Correlates for a Recombinant Protein Vaccine in the COVAIL TrialYouyi Fong, Lauren Dang, Bo Zhang, et al.
Vaccine|February 16, 2026
The neutralizing antibody titer correlate of COVID-19 risk in the COVID-19 variant immunologic landscape (COVAIL) trial was not modified by SARS-CoV-2 amino acid sequence distancesFei Heng, Craig A Magaret, Nadine G Rouphael, et al.
Nature Communications|January 17, 2025
Neutralizing antibody immune correlates in COVAIL trial recipients of an mRNA second COVID-19 vaccine boostBo Zhang, Youyi Fong, Lauren Dang, et al.
Nature Medicine|August 28, 2023
Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trialAngela R Branche, Nadine G Rouphael, David J Diemert, et al.
Medrxiv : the Preprint Server for Health Sciences|July 28, 2022
SARS-CoV-2 Variant Vaccine Boosters Trial: Preliminary AnalysesAngela R Branche, Nadine G Rouphael, David J Diemert, et al.
Pageof 10